Cannabis Law Report
NOVEMBER 16, 2021
As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), tumor necrosis factor receptor I (TNFRI) and IL-6.
Cannabis Law Report
JANUARY 5, 2022
3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. In the United States, the estimated cost of hospitalizations in individuals with sarcopenia is estimated at $40.4
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 15, 2022
They then go off to their separate sections, which are again all controlled by biometric fingerprint scanning for access,” Mr Benjamin said. Workers will have their fingerprints scanned before being allowed to access the turnstile to the Medifarm facility. ( “They get changed. ABC Rural: Jennifer Nichols ).
SMPL
MAY 26, 2020
CBD industry will be worth $16 billion by 2025. In the absence of oversight, the push to get more patients access to cannabis medicine — and bona fide CBD — has been co-opted by a push to make as much money as possible off the next big wellness fad. “At fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex.
Cannabis Law Report
OCTOBER 17, 2019
billion in 2025, according to Grandview Research. We’re acknowledging that making cannabis illegal didn’t work, and that a more effective way to protect the health and safety of Canadians is to provide adults with access to a regulated and safe cannabis supply for non-medical purposes.”. There are only so many Canadian consumers.”.
Expert insights. Personalized for you.
52 
Let's personalize your content